A twice daily intake regimen of aspirin provides a more stable inhibition within 24 hours after intake, compared to a once daily regimen.
ID
Bron
Verkorte titel
Aandoening
Cardiovascular patients myocardial infarcation angina pectoris
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
- PFA-200 parameters: closure time, flow slope, maximum rate of occlusion and area under the curve<br>
- Chrono-log LTA parameters: Amplitude of aggregation given in percentages and the area under the curve.<br>
- VerifyNow parameter: PRU <br>
- TBX2 serum levels. <br>
Achtergrond van het onderzoek
Objective: Analyze whether a twice daily regimen is superior to a once daily regime of aspirin when it comes to inhibiting platelet aggregation in cardiovascular patients
Study design: Single blinded, open label, randomized cross-overy study.
Study population: 75 outpatients from the cardiology department, taking 80 mg of acetylsalicylic acid once a day. 10 healthy subjects will be used to define baselines in the assays that are being used.
Intervention: Study participants will sequentially be allocated to three dosage regimens, A1, B, and C. The order of allocation will be decided via randomisation. Regimen A and B are designed to establish a baseline activability of the platelets under a once a day regime of acetylsalicylic acid. In regimen C participants are put on a twice daily dosage regimen. NB circadian rhythm has been taken into account. .
Main study parameters/endpoints: We will analyze whether a twice daily regimen is superior to a once daily regime of aspirin when it comes to inhibiting platelet aggregation in cardiovascular patients, as measured by the PFA-200, Chrono-log light transmission aggregometry, VerifyNow, and a TBX2 serum ELISA.
Doel van het onderzoek
A twice daily intake regimen of aspirin provides a more stable inhibition within 24 hours after intake, compared to a once daily regimen.
Onderzoeksopzet
Measured after 10 days of every intake regimen
Onderzoeksproduct en/of interventie
- Once daily intake regime 8.00 am, duration 10 days
- Once daily intake regime 8.00 pm, duration 10 days
- Twice daily intake regime 8.00 am & pm, duration 10 days
Algemeen / deelnemers
Jeske (J.J.K.) van Diemen
Amsterdam 1081 HV
The Netherlands
0031630179557 / 0630179557
jj.vandiemen@vumc.nl
Wetenschappers
Jeske (J.J.K.) van Diemen
Amsterdam 1081 HV
The Netherlands
0031630179557 / 0630179557
jj.vandiemen@vumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Outpatients being treated for stable cardiovascular disease by the cardiology department.
- Stable cardiovascular disease defined as: coronary artery disease, peripheral vascular disease or previous myocardial infarction.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Active bleeding
- Diabetes mellitus
- Thrombocytopenia
- Thrombocytosis
- Thrombopathy (e.g. von Willebrand disease, Glanzmann’s thrombasthenia and Bernard–Soulier syndrome)
- Any ischemic event or revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting) within the last six months.
- Alcohol intake the day before blood sampling.
- Non-compliance to the protocol
- Recent use of antiplatelet drugs, anticoagulants or drugs that are known to alter platelet function, other than aspirin (e.g. NSAID’s, tirofiban, eptifibatide, abciximab, beta-lactam antibiotics, dextran, SSRI’s, clomipramine & amitriptyline, dipyridamole, verapamil, diltiazem , ginkgo biloba, ginseng, St John’s wort).
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL4976 |
| NTR-old | NTR5114 |
| CCMO | NL49455.029.14 |
| OMON | NL-OMON42162 |